Celgene Corporation was founded by two scientists, David Stirling, Ph.D. and Sol Barer, Ph.D.

in

1986. Following its IPO (initial public offering) in 1987, the company has consistently delivered

breakthrough innovations in biotechnology in areas such as hematology, or blood-related diseases,

and oncology, or cancer. Celgene is headquartered in Summit, NJ and has strong presence in the

Americas, EMEA region, and Asia Pacific. Celgene Corporation is currently employing 7.47 K

people, both full and part-time (Macroaxis, n.d.). The Company's commercial-stage products

include “REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA

(apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension),

VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide).

Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and

inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic

modifier (Reuters, n.d.).”

References:

Macroaxis. (n.d.). Celgene Number of Employees. Retrieved April 1, 2018, from

www.macroaxis.com: https://www.macroaxis.com/invest/ratio/CELG--Number-of-

Employees

Reuters. (n.d.). Celgene Corp (CELG.O). Retrieved April 1, 2018, from www.reuters.com:

https://www.reuters.com/finance/stocks/company-profile/CELG.O